Biotech News

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure Medical (ICCM)IceCure Medical2026-06-02 12:30 ESTCompany update

ICCM (ICCM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is iccm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

IceCure Medical

Cryoablation Medical Technology IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal. ProSense The ProSense system uses liquid nitrogen-based probes to create a controlled ice ball around a tumor under image guidance. Breast Cancer Commercialization FDA clearance...

Recent company news

ICCMIceCure Medical2026-08-06 12:05 EST

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

ICCMIceCure Medical2026-08-05 12:30 EST

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

ICCMIceCure Medical2026-07-29 12:25 EST

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Stock data

Close: 3.08 USD
Market cap: 11.29M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States